NCT00057317

Brief Summary

The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 5 to 20 mg/day will be studied.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Timeline
Completed

Started Dec 2001

Geographic Reach
11 countries

117 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2001

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

March 31, 2003

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 1, 2003

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2003

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2003

Completed
Last Updated

August 24, 2016

Status Verified

August 1, 2016

Enrollment Period

2 years

First QC Date

March 31, 2003

Last Update Submit

August 23, 2016

Conditions

Interventions

Eligibility Criteria

Age35 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 35 to 75
  • Type 2 diabetes for longer than 3 months
  • HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening
  • FPG (fasting plasma glucose) greater than 126 mg/dL at screening
  • BMI (body mass index) less than 40 kg/square meter

You may not qualify if:

  • Type I diabetes
  • Type 2 diabetes patients currently treated with insulin
  • Type 2 diabetes patients currently or previously treated with Actos, Avandia or Rezulin
  • FPG (fasting plasma glucose) greater than 270 mg/dL at baseline
  • Impaired liver or kidney function
  • Triglycerides greater than 600 mg/dL
  • Uncontrolled hypertension
  • Pregnant or lactating women
  • Women not using adequate contraception

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (117)

Unknown Facility

Huntsville, Alabama, 35801, United States

Location

Unknown Facility

Mesa, Arizona, 85206, United States

Location

Unknown Facility

Scottsdale, Arizona, 85251, United States

Location

Unknown Facility

Tucson, Arizona, 85710, United States

Location

Unknown Facility

Tucson, Arizona, 85723, United States

Location

Unknown Facility

Encino, California, 91436, United States

Location

Unknown Facility

Fountain Valley, California, 92708, United States

Location

Unknown Facility

Fremont, California, 94538, United States

Location

Unknown Facility

Fresno, California, 93720, United States

Location

Unknown Facility

Irvine, California, 92618, United States

Location

Unknown Facility

Modesto, California, 95355, United States

Location

Unknown Facility

Pasadena, California, 91106, United States

Location

Unknown Facility

San Bruno, California, 94066, United States

Location

Unknown Facility

Santa Rosa, California, 95405, United States

Location

Unknown Facility

Sunnyvale, California, 94086, United States

Location

Unknown Facility

Hamden, Connecticut, 06518, United States

Location

Unknown Facility

Norwalk, Connecticut, 06850, United States

Location

Unknown Facility

Newark, Delaware, 19713, United States

Location

Unknown Facility

Hollywood, Florida, 33021, United States

Location

Unknown Facility

Jacksonville, Florida, 32204, United States

Location

Unknown Facility

Ocala, Florida, 34471, United States

Location

Unknown Facility

West Palm Beach, Florida, 33401, United States

Location

Unknown Facility

Atlanta, Georgia, 30322, United States

Location

Unknown Facility

Lawrenceville, Georgia, 30045, United States

Location

Unknown Facility

Honolulu, Hawaii, 96813, United States

Location

Unknown Facility

Indianapolis, Indiana, 46214-2985, United States

Location

Unknown Facility

Overland Park, Kansas, 66211, United States

Location

Unknown Facility

New Orleans, Louisiana, 70121, United States

Location

Unknown Facility

Boston, Massachusetts, 02215, United States

Location

Unknown Facility

Kansas City, Missouri, 64111, United States

Location

Unknown Facility

St Louis, Missouri, 63104, United States

Location

Unknown Facility

St Louis, Missouri, 63110, United States

Location

Unknown Facility

Billings, Montana, 59101, United States

Location

Unknown Facility

Omaha, Nebraska, 68198-3032, United States

Location

Unknown Facility

Las Vegas, Nevada, 89102, United States

Location

Unknown Facility

Trenton, New Jersey, 08611, United States

Location

Unknown Facility

Albuquerque, New Mexico, 87106, United States

Location

Unknown Facility

Buffalo, New York, 14209, United States

Location

Unknown Facility

New Hyde Park, New York, 11040, United States

Location

Unknown Facility

Rochester, New York, 14609, United States

Location

Unknown Facility

Charlotte, North Carolina, 28209, United States

Location

Unknown Facility

Durham, North Carolina, 27710, United States

Location

Unknown Facility

Greenville, North Carolina, 27858-4354, United States

Location

Unknown Facility

Morrisville, North Carolina, 27560, United States

Location

Unknown Facility

Portland, Oregon, 97201, United States

Location

Unknown Facility

Tualatin, Oregon, 97062, United States

Location

Unknown Facility

Camp Hill, Pennsylvania, 17011, United States

Location

Unknown Facility

Connellsville, Pennsylvania, 15425, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19104, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19107, United States

Location

Unknown Facility

East Providence, Rhode Island, 02914, United States

Location

Unknown Facility

Greer, South Carolina, 29651, United States

Location

Unknown Facility

Memphis, Tennessee, 38119, United States

Location

Unknown Facility

Dallas, Texas, 75230, United States

Location

Unknown Facility

El Paso, Texas, 79902, United States

Location

Unknown Facility

Houston, Texas, 77030, United States

Location

Unknown Facility

Midland, Texas, 79705, United States

Location

Unknown Facility

San Antonio, Texas, 78229-4801, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

San Antonio, Texas, 78284, United States

Location

Unknown Facility

Lebanon, Virginia, 24266, United States

Location

Unknown Facility

Richmond, Virginia, 23294, United States

Location

Unknown Facility

Virginia Beach, Virginia, 23451, United States

Location

Unknown Facility

Edmonds, Washington, 98026, United States

Location

Unknown Facility

Wenatchee, Washington, 98801, United States

Location

Unknown Facility

Pleven, 5800, Bulgaria

Location

Unknown Facility

Plovdiv, 4002, Bulgaria

Location

Unknown Facility

Sofia, 1233, Bulgaria

Location

Unknown Facility

Sofia, 1431, Bulgaria

Location

Unknown Facility

Calgary, Alberta, T3B 0M3, Canada

Location

Unknown Facility

Winnipeg, Manitoba, R3E 3P4, Canada

Location

Unknown Facility

Halifax, Nova Scotia, B3H 1V7, Canada

Location

Unknown Facility

Courtice, Ontario, L1E 3C3, Canada

Location

Unknown Facility

Ottawa, Ontario, K1Y 4E9, Canada

Location

Unknown Facility

Windsor, Ontario, N8X 1K4, Canada

Location

Unknown Facility

Laval, Quebec, H7T 2P5, Canada

Location

Unknown Facility

Montreal, Quebec, H1T 2M4, Canada

Location

Unknown Facility

Montreal, Quebec, H3T 1E2, Canada

Location

Unknown Facility

Sainte-Foy, Quebec, G1V 4G2, Canada

Location

Unknown Facility

Sherbrooke, Quebec, J1G 5K2, Canada

Location

Unknown Facility

St. John's, A1B 3V6, Canada

Location

Unknown Facility

Tallinn, 10138, Estonia

Location

Unknown Facility

Tartu, 50406, Estonia

Location

Unknown Facility

Tartu, 50708, Estonia

Location

Unknown Facility

Võru, 65609, Estonia

Location

Unknown Facility

Ogre, 5001, Latvia

Location

Unknown Facility

Talsi, 3201, Latvia

Location

Unknown Facility

Tukums, 3100, Latvia

Location

Unknown Facility

Valmiera, LV-4201, Latvia

Location

Unknown Facility

Kaunas, 3036, Lithuania

Location

Unknown Facility

Kaunas, 3040, Lithuania

Location

Unknown Facility

Kaunas, 3042, Lithuania

Location

Unknown Facility

Vilnius, Lithuania

Location

Unknown Facility

Guadalajara, 44280, Mexico

Location

Unknown Facility

Guadalajara, 44349, Mexico

Location

Unknown Facility

Mexico City, 03100, Mexico

Location

Unknown Facility

Mexico City, 06700, Mexico

Location

Unknown Facility

Mexico City, 14050, Mexico

Location

Unknown Facility

Mérida, 97000, Mexico

Location

Unknown Facility

Monterrey, 64320, Mexico

Location

Unknown Facility

Monterrey, 64410, Mexico

Location

Unknown Facility

Monterrey, 64460, Mexico

Location

Unknown Facility

Pachuca, Hidalgo, 42039, Mexico

Location

Unknown Facility

Tijuana, 22320, Mexico

Location

Unknown Facility

Panama City, Panama

Location

Unknown Facility

Ponce, 00732-7994, Puerto Rico

Location

Unknown Facility

Arad, 2900, Romania

Location

Unknown Facility

Brasov, 500326, Romania

Location

Unknown Facility

Bucharest, 020475, Romania

Location

Unknown Facility

Bucharest, 7000, Romania

Location

Unknown Facility

Galati, 6200, Romania

Location

Unknown Facility

Ploieşti, 2000, Romania

Location

Unknown Facility

Târgovişte, 0200, Romania

Location

Unknown Facility

Târgu Mureş, 4300, Romania

Location

Unknown Facility

Bracknell, RG12 1HX, United Kingdom

Location

Unknown Facility

Nottingham, NG2 3HF, United Kingdom

Location

Unknown Facility

Plymouth, PL6 8BX, United Kingdom

Location

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

March 31, 2003

First Posted

April 1, 2003

Study Start

December 1, 2001

Primary Completion

December 1, 2003

Study Completion

December 1, 2003

Last Updated

August 24, 2016

Record last verified: 2016-08

Locations